Clot-buster treatment for stroke patients on blood thinners
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether a stronger clot-busting drug (tenecteplase) is safe and works for people who have had a stroke while taking a common blood thinner. If you qualify, you may get this treatment within a few hours of your stroke to help improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have had a stroke caused by a blood clot that causes clear disability.
- You can start treatment within 4.5 hours of when you were last known to be well.
- You are currently taking a DOAC blood thinner (such as Eliquis, Xarelto, Pradaxa, or Savaysa) and took your last dose within the past 48 hours.
- You have not had bleeding in the brain, major head trauma, or a stroke in the last 3 months.
- You do not have severe kidney or liver disease, or a bleeding disorder.
- You are not pregnant and do not have any condition that would make clot-busting treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.
This trial tests whether a clot-dissolving drug called tenecteplase can improve recovery for people who had a large-vessel ischemic stroke 4.5 to 24 hours earlier and can’t have a mechanical clot removal procedure in time. If you join, you’ll get either tenecteplase or standard medical care, and the study will track your recovery and safety.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the blocked blood vessel in the brain can help people with a medium-sized vessel occlusion stroke. The drug may help restore blood flow and reduce disability, and it is given within 24 hours of symptom onset.
This trial tests a clot-busting drug called tenecteplase given later than usual (4.5 to 9 hours after stroke symptoms) to people whose MRI shows the stroke may still be reversible. The goal is to see if it helps reduce disability after a stroke.
This trial tests whether a clot-busting medication given through a vein (intravenous thrombolysis) can safely treat acute ischemic stroke within 24 hours in people who have taken a newer oral blood thinner (NOAC) within the last 4 to 48 hours.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.